久久亚洲国产成人影院-久久亚洲国产的中文-久久亚洲国产高清-久久亚洲国产精品-亚洲图片偷拍自拍-亚洲图色视频

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Companies

Chinese biotech firm BeiGene's plans move into high gear

By Qiu Quanlin in Guangzhou | chinadaily.com.cn | Updated: 2020-12-17 10:34
Share
Share - WeChat
A technician carries out a test at a pharmaceutical company in Beijing. [Photo/Xinhua]

Construction of the third plant of BeiGene Ltd, a Chinese biotechnology company, along with the completion of its second plant in Guangzhou, the capital of Guangdong province, will help boost the company's production capacity and upgrade its manufacturing technique, according to a senior executive.

BeiGene announced construction of the third plant and completion of its second one in its biopharmaceutical manufacturing base in Guangzhou on Wednesday.

"The second and third plants will enable us to produce verified biopharmaceutical products, helping us reduce production cost and increase efficiency," said Michael Garvey, vice-president of BeiGene.

After the completion of its second plant, BeiGene's manufacturing base in Guangzhou has a production capacity of 24,000 liters of biopharmaceuticals, according to the company sources.

The base will become one of the largest domestic biopharmaceutical manufacturing hubs, as its production capacity is expected to increase to 64,000 liters, following the completion of its third plant.

"Advanced facilities, along with introduction of artificial intelligence and automation techniques, helped us to develop innovative biopharmaceutical products, which are already witnessing high demand both on the Chinese and global markets," said Garvey.

Founded in Beijing in 2010 as a biotechnology company, BeiGene completed construction of a small molecule manufacturing facility in Suzhou of Jiangsu province in 2016 and the initial phase of a bio-manufacturing base in Guangzhou in 2019.

The company's self-developed cancer drug, known as Brukinsa (zanubrutinib) in capsule form, was granted market access by the National Medical Products Administration in June this year.

The drug is for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy, and also for adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

In November last year, the independently-developed new cancer therapy also received approval from the US Food and Drug Administration as a treatment for MCL in adult patients who have received at least one prior therapy.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 欧美久久视频 | 一级久久 | 三级国产在线观看 | 亚洲精品自产拍在线观看 | 一级做人爱a视频正版免费 一级做性色a爱片久久片 | 国产高清在线看 | 一级片一区 | 久久久久久久性高清毛片 | 亚洲精品区一区二区三区四 | 深爱五月开心网亚洲综合 | 欧美成人免费香蕉 | 国产欧美va欧美va香蕉在线观 | 久久免费手机视频 | 日韩性视频网站 | 久草视频在线资源站 | 国产人成在线视频 | 国产成人tv在线观看 | 一级毛片美国一级j毛片不卡 | 美女张开腿给男人捅 | 日韩专区欧美 | 台湾精品视频在线观看 | 国产成人精选免费视频 | 久操免费在线视频 | 国产精品二区在线 | 国产在线观看一区二区三区四区 | 怡红院免费va男人的天堂 | 中文字幕成人在线观看 | 免费看一级欧美激情毛片 | 欧美色偷偷 | 中文字幕一级毛片 | 国产精品美女一区二区 | 国产成人久久精品二区三区 | 美女视频网站免费播放视 | 2022国产精品网站在线播放 | 国产在线美女 | 国产一区精品在线 | 日本人成18在线播放 | 视频一区在线观看 | 毛片韩国 | 91香蕉国产亚洲一区二区三区 | 日本三级中文字幕 |